<DOC>
	<DOC>NCT01696695</DOC>
	<brief_summary>This observational study will evaluate the efficacy and safety of different capecitabine based chemotherapies, alone or in combination with other therapies, as first line treatment of metastatic colorectal cancer in participants during everyday clinical practice.</brief_summary>
	<brief_title>An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Participants with newly diagnosed mCRC who have started firstline capecitabinebased chemotherapy in accordance with the current Hungarian label History of serious or unexpected reaction to fluoropyrimidine therapy Hypersensitivity to the active ingredient of Xeloda or to any of the excipients of the product, or to fluorouracil Known dihydropyrimidine dehydrogenase deficiency Pregnancy or lactation Inadequate bone marrow, hepatic or renal function Treatment with sorivudine or its chemical analogues (for example, brivudine) If any contraindication for any drug used in the combination treatment schedules is present, the drug in question cannot be used</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>